This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Mona Patel
Mona Patel
Washington +1 202 662 5797 Download V-card

Mona Patel has extensive experience representing clients in large scale federal and state investigations brought by enforcement authorities, related qui tam or follow-on consumer protection litigation, internal investigations and compliance matters. She advises clients in the life sciences, defense, technology and manufacturing industries on a wide variety of white collar matters.

Anti-Corruption and Trade Controls

  • Conduct risk assessments and developed comprehensive anti-corruption compliance programs, and provide day-to-day anti-corruption compliance advice for companies in the life sciences, chemical, consumables, automotive and technology sectors.
  • Advise companies on development and implementation of effective and integrated global compliance programs and targeted anti-corruption compliance procedures.
  • Assist companies with anti-corruption due diligence related to mergers, acquisitions, asset purchases and joint ventures.
  • Led internal FCPA investigations for global automotive and engineering services, consumables and manufacturing companies.
  • Led internal export controls investigation and provide export controls compliance advice for global manufacturing company.

Healthcare Fraud and Compliance

  • Served as Board-appointed monitor for a national health care company under criminal and civil investigation; representation included systems reviews and assessment of compliance program, policies and practices, internal investigations of alleged misconduct by executives, and recommendations as to corrective actions.
  • Represented GlaxoSmithKline in federal criminal and civil investigations and 2012 global resolution of three investigations concerning sales, marketing, pricing and FDA reporting practices.
  • Represented GlaxoSmithKline in civil investigation and 2010 resolution concerning manufacturing practices at the company’s former manufacturing facility in Puerto Rico.
  • Represented company in related consumer protection investigations and settlement with 37 states.
  • Defended Leiner Health Products Inc. in a criminal prosecution of alleged violations of current Good Manufacturing Practices (cGMPs) relating to the manufacture of over-the-counter drugs.
  • Represent medical device company in ongoing criminal and civil investigations concerning sales and marketing practices.
  • Counsel major pharmaceutical manufacturers on Corporate Integrity Agreement requirements, including reportable events provisions.
  • Conduct internal investigations on behalf of major pharmaceutical manufacturers relating to potential violations of sales and marketing policies.
  • Counsel health care providers on elements of an effective compliance program and compliance best practices.


  • Represented GlaxoSmithKline in multi-district litigation challenging AWP (average wholesale price) practices.
  • Represented several pharmaceutical companies in federal and state false claims act litigation concerning sales and marketing practices and FDA reporting.
  • Represented pharmaceutical manufacturer in qui tam and employment litigation with potential collateral consequences in government investigations.
  • Represented technology company in fraudulent inducement claim brought by former founder of an acquired company.